157 related articles for article (PubMed ID: 36662390)
1. Correlation analysis and prognostic value of miR-29a-3p expression and CYP2C19 genotypes in exfoliated cells from tongue coating of patients with gastroesophageal reflux disease.
Zhang A; Liu W; Niu L; Zhu L; Yang L; Li X
Genes Genomics; 2023 May; 45(5):673-680. PubMed ID: 36662390
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.
Yu D; Green B; Tolleson WH; Jin Y; Mei N; Guo Y; Deng H; Pogribny I; Ning B
Biochem Pharmacol; 2015 Nov; 98(1):215-23. PubMed ID: 26296572
[TBL] [Abstract][Full Text] [Related]
3. miR-203 Expression in Exfoliated Cells of Tongue Coating Represents a Sensitive and Specific Biomarker of Gastroesophageal Reflux Disease.
Yan X; Zhu S; Zhang H
Gastroenterol Res Pract; 2016; 2016():2349453. PubMed ID: 27667995
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
[TBL] [Abstract][Full Text] [Related]
5. Expression of Serum Exosomal and Esophageal MicroRNA in Rat Reflux Esophagitis.
Uemura R; Murakami Y; Hashimoto A; Sawada A; Otani K; Taira K; Hosomi S; Nagami Y; Tanaka F; Kamata N; Yamagami H; Tanigawa T; Watanabe T; Taguchi YH; Fujiwara Y
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28757556
[TBL] [Abstract][Full Text] [Related]
6. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
[TBL] [Abstract][Full Text] [Related]
7. Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.
Furuta T; Sugimoto M; Shirai N
Mol Diagn Ther; 2012 Aug; 16(4):223-34. PubMed ID: 22873740
[TBL] [Abstract][Full Text] [Related]
8. Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.
Franciosi JP; Mougey EB; Williams A; Gomez Suarez RA; Thomas C; Creech CL; George K; Corao D; Lima JJ
Eur J Pediatr; 2018 Jan; 177(1):69-77. PubMed ID: 29209919
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
Yamano HO; Matsushita HO; Yanagiwara S
J Gastroenterol Hepatol; 2008 Apr; 23(4):534-40. PubMed ID: 17725594
[TBL] [Abstract][Full Text] [Related]
10. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
[TBL] [Abstract][Full Text] [Related]
13. Identifying miRNAs Associated with the Progression of Keloid through mRNA-miRNA Network Analysis and Validating the Targets of miR-29a-3p in Keloid Fibroblasts.
He Y; Zhang Z; Yin B; Li S; Wang P; Lan J; Lian W; Jia C
Biomed Res Int; 2022; 2022():6487989. PubMed ID: 35872873
[TBL] [Abstract][Full Text] [Related]
14. Expression pattern of
Chu X; Wu D; Zhang C; Hu S
Scand J Clin Lab Invest; 2023 Jul; 83(4):207-211. PubMed ID: 37093849
[TBL] [Abstract][Full Text] [Related]
15. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
[TBL] [Abstract][Full Text] [Related]
16. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.
Saitoh T; Otsuka H; Kawasaki T; Endo H; Iga D; Tomimatsu M; Fukushima Y; Katsube T; Ogawa K; Otsuka K
Hepatogastroenterology; 2009; 56(91-92):703-6. PubMed ID: 19621685
[TBL] [Abstract][Full Text] [Related]
17. Urinary miRNA-29a-3p levels are associated with metabolic parameters via regulation of IGF1 in patients with metabolic syndrome.
Lin X; Luo C; He D; Matro E; Chen Q; Li H; Zhou J
Biomed Rep; 2019 Apr; 10(4):250-258. PubMed ID: 30972221
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.
Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Ikuma M; Shirai N; Watanabe H; Umemura K; Kimura M; Hishida A
Eur J Clin Pharmacol; 2009 Jul; 65(7):693-8. PubMed ID: 19259653
[TBL] [Abstract][Full Text] [Related]
19. Acute and post-acute phase of COVID-19: Analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC.
Donyavi T; Bokharaei-Salim F; Baghi HB; Khanaliha K; Alaei Janat-Makan M; Karimi B; Sadri Nahand J; Mirzaei H; Khatami A; Garshasbi S; Khoshmirsafa M; Jalal Kiani S
Int Immunopharmacol; 2021 Aug; 97():107641. PubMed ID: 33895478
[TBL] [Abstract][Full Text] [Related]
20. MiR-1236-3p serves as a new diagnostic and prognostic biomarker for gastric cancer.
An JX; Ma ZS; Ma MH; Shao S; Cao FL; Dai DQ
Cancer Biomark; 2019; 25(2):127-132. PubMed ID: 31045511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
